163 related articles for article (PubMed ID: 34073907)
1. A Longitudinal Study of Breakthrough Cancer Pain: An Extension of IOPS-MS Study.
Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G
J Clin Med; 2021 May; 10(11):. PubMed ID: 34073907
[TBL] [Abstract][Full Text] [Related]
2. The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.
Mercadante S; Maltoni M; Russo D; Adile C; Ferrera P; Rossi R; Rosati M; Casuccio A
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801478
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.
Mercadante S; Caraceni A; Masedu F; Scipioni T; Aielli F
Oncologist; 2020 Feb; 25(2):156-160. PubMed ID: 31862860
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Mercadante S; Masedu F; Valenti M; Aielli F
Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study.
Mercadante S; Masedu F; Valenti M; Aielli F
J Clin Med; 2020 May; 9(5):. PubMed ID: 32375331
[TBL] [Abstract][Full Text] [Related]
6. Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study.
Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1134-1139. PubMed ID: 36808361
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain.
Mercadante S; Adile C; Masedu F; Valenti M; Aielli F
J Pain Symptom Manage; 2019 May; 57(5):966-970. PubMed ID: 30822530
[TBL] [Abstract][Full Text] [Related]
9. Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients.
Mercadante S; Adile C; Torta R; Varetto A; Fulfaro F; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jan; 29(1):93-7. PubMed ID: 23198976
[TBL] [Abstract][Full Text] [Related]
10. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
11. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
[TBL] [Abstract][Full Text] [Related]
13. Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies.
Mercadante S; Valle A; Porzio G; Aielli F; Adile C; Ficorella C; Raineri M; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):667-71. PubMed ID: 23551065
[TBL] [Abstract][Full Text] [Related]
14. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.
Villarroel PG; Padró JG; Marquina G; Jáñez NM; González EE; Antón A; Sánchez MB; Cáceres AR; López-López R; Cornejo RE; García PB; Fabregat RM; Fernández BC; Bermudo CL; Camps C
Future Oncol; 2022 Nov; 18(35):3913-3927. PubMed ID: 36537885
[TBL] [Abstract][Full Text] [Related]
15. Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study.
Mazzotta M; Filetti M; Piras M; Mercadante S; Marchetti P; Giusti R
Cancer Manag Res; 2022; 14():1237-1245. PubMed ID: 35356594
[TBL] [Abstract][Full Text] [Related]
16. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A
J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough pain in patients with abdominal cancer pain.
Mercadante S; Adile C; Giarratano A; Casuccio A
Clin J Pain; 2014 Jun; 30(6):510-4. PubMed ID: 24281289
[TBL] [Abstract][Full Text] [Related]
19. Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study.
Katz NP; Gajria KL; Shillington AC; Stephenson JJ; Harshaw Q
Postgrad Med; 2017 Jan; 129(1):32-39. PubMed ID: 27846789
[TBL] [Abstract][Full Text] [Related]
20. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G
J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
